Ranibizumab is a High-Purity Anti-VEGF Biologic for Ophthalmic Applications
- Bulk production capacity for commercial and research needs
- Available in various concentrations & formulations as per client requirements
- Produced under internationally recognized Good Manufacturing Practices (GMP)
Product application
- • Age-Related Macular Degeneration (AMD)
- • Diabetic Macular Edema (DME)
- • Retinal Vein Occlusion (RVO)
High-Purity Anti-VEGF Biologic for Ophthalmic Applications
Ranibizumab is a recombinant, humanized monoclonal antibody fragment (Fab) that specifically inhibits vascular endothelial growth factor A (VEGF-A). It is widely used in the treatment of neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and other retinal vascular diseases.
Why Choose us?
- Advanced bioprocessing technology ensuring high yield & purity
- Expertise in monoclonal antibody fragment production Available in bulk quantities to meet pharmaceutical needs.
- End-to-end regulatory & technical support
Key features & Benefits
- • High Purity & Quality – Manufactured using state-of-the-art peptide synthesis technology.
- • GMP Compliance Production – Adheres to stringent Good Manufacturing Practices.
- • Customized Solutions – Available in bulk quantities to meet pharmaceutical needs.
- • Global Supply & Compliance – Compliant with international pharmacopeial standards.
Specifications
- • Molecular Weight: ~48 kDa
- • Expression System: CHO (Chinese Hamster Ovary) cells
- • Purity: ≥ 98% (by HPLC/SEC)
- • Formulation: Lyophilized powder / Liquid solution
- • Storage Conditions: -20°C to -80°C
Regulatory Support
- • Advanced bioprocessing technology ensuring high yield & purity
- • Expertise in monoclonal antibody fragment production
- • End-to-end regulatory & technical support
Our trusted partners
